November 18, 2026
Health news, explained with evidence
LIVE

Clinical Trial Examines Adjuvant Therapy for Solitary Plasmacytoma of Bone

❤️ Conditions & Care 2 min read 👁 5

Researchers from the Alliance for Clinical Trials in Oncology have evaluated whether adding systemic therapies to zoledronic acid delays progression to multiple myeloma in patients with solitary plasmacytoma of bone.

❤️Conditions & Care

Key points

  • Phase III trial evaluates systemic therapy addition for SPB
  • Compares multi-drug regimen with zoledronic acid alone
  • Aims to address progression risks to multiple myeloma

A recent phase III clinical trial, known as Alliance A061402, has explored potential treatment enhancements for solitary plasmacytoma of bone (SPB), a localized bone tumor made of clonal plasma cells. While definitive radiation therapy remains the standard approach for managing SPB, many patients eventually progress to overt multiple myeloma. To investigate whether additional medical interventions might delay this progression, researchers designed a study comparing the combination of ixazomib, lenalidomide, dexamethasone, and zoledronic acid against zoledronic acid alone.

The study enrolled adult participants who had completed localized radiation therapy and met specific baseline lab and health criteria, including having fewer than 10 percent clonal plasma cells in the bone marrow and a single bone lesion. Participants were randomized to receive either the multi-drug systemic regimen alongside zoledronic acid or zoledronic acid alone for up to six 28-day cycles.

As an observational and clinical evaluation of treatment sequencing, the findings contribute to ongoing discussions regarding the role of adjuvant systemic treatments after radiation. Because SPB management varies and progression timelines can differ based on cytogenetics and other individual risk factors, researchers continue to study how best to optimize long-term outcomes without exposing patients to unnecessary side effects.

Always talk to a qualified healthcare provider for personal medical advice, diagnosis, and individualized treatment decisions.

What to know:

  • Solitary plasmacytoma of bone is a localized tumor that carries a risk of progressing to multiple myeloma over time.
  • The Alliance A061402 phase III trial assessed whether combining oral systemic therapies with zoledronic acid improves progression outcomes following radiation therapy.
  • Medical professionals weigh the potential benefits of adjuvant treatments against side effect risks, emphasizing personalized care plans.

Source Nature Health Sciences — nature.com/articles/s41408-026-01674-w ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.